Plaque Psoriasis Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2030

List of Contents

List of Tables

List of Figures

1 Plaque Psoriasis: Executive Summary – Updated July 2025, Based on Events Up to July 25, 2025

1.1 Summary of changes

1.2 PsO market to experience conservative growth from 2020–30

1.3 New players to enter a saturated field

1.4 Opportunities remain for undertreated patient populations

1.5 Innovator small molecules dominate the late-stage pipeline

1.6 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods.

4.5 Epidemiological forecast for PsO (2020–30)

4.5.1 Lifetime diagnosed prevalent cases of PsO

4.5.2 Age-specific lifetime diagnosed prevalent cases of PsO

4.5.3 Sex-specific lifetime diagnosed prevalent cases of PsO

4.5.4 Lifetime diagnosed prevalent cases of PsO by severity in the adult population

4.5.5 Lifetime diagnosed prevalent cases of PsO with PsA in the adult population

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of analysis

4.6.4 Strengths of analysis

5 Disease Management

5.1 Diagnosis

5.2 Treatment

6 Competitive Assessment

6.1 Overview

6.1.1 TNF inhibitors

6.1.2 IL-17 inhibitors

6.1.3 IL-12/23 inhibitors and IL-23 inhibitors

6.1.4 PDE4 inhibitors

6.1.5 Kinase inhibitors

6.1.6 Other disease modifying therapies

6.2 Biosimilars

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Cost-effective therapies

7.3 Efficacious therapies for treatment refractory patients

7.4 Lack of innovative topical therapies

7.5 Treatment options for mild PsO patients

8 R&D Strategies

8.1 Development shifts away from injectable biologics

8.2 New players enter the late-stage pipeline

8.3 Clinical trials design

8.3.1 Robust clinical endpoints

8.3.2 Long-term patient follow-up

8.3.3 Active comparator trials

9 Pipeline Assessment – Updated July 2025, Based on Events Up to July 25, 2025

9.1 Overview

9.2 Promising drugs in clinical development

9.2.1 Sonelokimab

9.2.2 Icotrokinra

9.2.3 TAK-279

9.2.4 Orismilast

9.2.5 Piclidenoson

9.3 Other drugs of note

9.3.1 Balinatunfib (SAR441566)

9.3.2 DC-806

9.3.3 Mirikizumab

9.3.4 Brepocitinib tosylate

10 Pipeline Valuation Analysis – Updated July 2025, Based on Events Up to July 25, 2025

10.1 Overview

10.2 Competitive assessment

10.2.1 Biologic medications

10.2.2 Small molecule therapeutics

11 Current and Future Players – Updated July 2025, Based on Events Up to July 25, 2025

11.1 Overview

11.2 Deal-making trends

12 Market Outlook – Updated July 2025, Based on Events Up to July 25, 2025

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Abbreviations

13.2 Methodology

13.2.1 Forecasting methodology

13.3 Primary research – KOLs and payors interviewed for this report

13.3.1 KOLs

13.3.2 Payers

13.4 Bibliography

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Epidemiologist

13.6.4 Reviewers

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

About GlobalData

Contact Us

Table 1: Plaque psoriasis: key metrics in the 7MM

Table 2: Summary of changes to PsO: Seven-Market Drug Forecast and Analysis Report

Table 3: Risk factors and comorbidities for PsO

Table 4: Classification of PsO by BSA

Table 5: Treatment guidelines for plaque psoriasis

Table 6: Top completed deals in PsO market by value, 2018–23

Table 7: PsO market – global drivers and barriers, 2020–30

Table 8: Key events impacting sales for PsO in the US, 2020–30

Table 9: PsO market – drivers and barriers in the US, 2020–30

Table 10: Key events impacting sales for PsO in the 5EU, 2020–30

Table 11: PsO market – drivers and barriers in the 5EU, 2020–30

Table 12: Key events impacting sales for PsO in Japan, 2020–30

Table 13: PsO market – drivers and barriers in Japan, 2020–30

Table 14: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for PsO in 2020 and 2030

Figure 2: Analysis of the company portfolio gap in PsO during the forecast period

Figure 3: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira

Figure 4: Competitive assessment of the pipeline small molecule drugs benchmarked against the SOC, Otezla

Figure 5: Biologic and small molecule targets in the treatment of PsO

Figure 6: 7MM, lifetime diagnosed prevalence of pediatric PsO (%), boys and girls, ages ≤17 years, 2020

Figure 7: 7MM, lifetime diagnosed prevalence of adult PsO (%), men and women, ages ≥18 years, 2020

Figure 8: Sources used for lifetime diagnosed prevalent cases of pediatric PsO

Figure 9: Sources used and not used for lifetime diagnosed prevalent cases of PsO in adults

Figure 10: Sources used for lifetime diagnosed prevalent cases of PsO by severity among adults

Figure 11: Sources used for lifetime diagnosed prevalent cases of PsO with PsA among adults

Figure 12: 7MM, lifetime diagnosed prevalent cases of PsO, men and women, all ages, 2020 (N)

Figure 13: Age-specific lifetime diagnosed prevalent cases of PsO, 7MM, men and women, 2020 (N)

Figure 14: 7MM, sex-specific lifetime diagnosed prevalent cases of PsO, all ages, 2020 (N)

Figure 15: 7MM, lifetime diagnosed prevalent cases of PsO by severity, men and women, ≥18 years, 2020

Figure 16: 7MM, lifetime diagnosed prevalent cases of PsO with psoriatic arthritis, men and women, ≥18 years, 2020 (N)

Figure 17: Overall treatment algorithm for PsO as approved by the EMA

Figure 18: Unmet needs and opportunities in PsO

Figure 19: Overview of the development pipeline in PsO

Figure 20: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PsO in the 7MM during the forecast period

Figure 21: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira

Figure 22: Competitive assessment of the pipeline small molecules drugs benchmarked against the SOC, Otezla

Figure 23: Analysis of the company portfolio gap in PsO during the forecast period

Figure 24: Global (7MM) sales forecast by country for PsO in 2020 and 2030

Figure 25: Sales forecast by class for PsO in the US in 2020 and 2030

Figure 26: Sales forecast by class for PsO in the 5EU in 2020 and 2030

Figure 27: Sales forecast by class for PsO in Japan in 2020 and 2030